These data suggest that variation in the mechanism of action of T-DXd between cells with and without HER2 amplification or differences in intrinsic cancer cell characteristics (e.g., HER2 expression) may help to explain differences in outcomes observed in this study41. The gene discussed is ERBB2; the disease is cancer.